



Coming to grips with unfamiliar uncertainties of a new predictive toxicology paradigm

Maurice Whelan

European Commission Joint Research Centre



EUR
ECVAM
European Union Reference Laboratory
for Alternatives to Animal Testing

Shaping the future of food safety together"

EFSA@EXPO, Milano 2015




European
Commission

Systems Toxicology Unit – Support to policy focus

Regulation of Chemicals* and the Protection of Animals

- Animal-free methodology to assess the hazard posed to consumers, workers and the environment
- Advancing safety assessment science to support regulatory decision making
- Facilitating industry to comply with regulation while striving for innovation and competitiveness

*Industrial chemicals, cosmetic ingredients, food constituents, pesticides, biocides, drugs





Established under the Directive 2010/63/EU on the protection of animals used for scientific purposes

The European Union Reference Laboratory for Alternatives to Animal Testing

Responsibilities

- Guide research
- Coordinate validation
- Disseminate information
- Facilitate stakeholder dialogue
- Promote international acceptance









JRC SCIENCE AND POLICY REPORT

EURL ECVAM Status Report on the Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches (2015)

Valérie Zang, Bertrand Desprez, João Barroso, Susanne Belz, Elisabeth Berggren, Camilla Bernasconi, Jos Bessens, Stephanie Bopp, Silvia Casati, Sandra Coecke, Raffaella Convi, Coralie Dumont, Varvara Gouliamou, Claudius Griesinger, Marlies Halder, Annett Janusch-Roi, Aude Kienzler, Brigitte Landesmann, Federica Madia, Anne Mikkelsen, Sharon Munn, Anna Price, Pilar Prieto, Michael Schäffer, Jutta Triebel, Clemens Wittwehr, Andrew Worth and Maurice Whelan

September 2015



Extrapolating
from early to
late effect

Extrapolating across
dosing duration

Extrapolating
across dosing
patterns


Conventional Toxicology

Determination
of a PoD

Extrapolating
to low-effect
levels




Chemical



Animal model

histopathology



Observation of
effects

Extrapolating
across exposure
metrics

Extrapolating
across agents

Estimating
Intra-species
variability

Sources of 'familiar' uncertainty

Inter-species
extrapolation

Estimating the impact
of missing studies

Extrapolating
from *in vitro* or
in chemico to *in vivo* data


WHO-IPCS (2014) Guidance document on
evaluating and expressing uncertainty in
hazard characterization.



European
Commission

Predictive Toxicology

Organ-on-a-chip




Cell cultures




'OMICS

MoA knowledge

Adverse
Outcomes



Cheminformatics &
Comp. chemistry



Exposure modeling




European
Commission

Integrated Approaches to Testing and Assessment (IATA): Proposed Working Definition

A hypothesis-driven framework for hazard identification, hazard characterisation and/or safety assessment of a chemical or group of chemicals, which strategically integrates and weights all relevant existing data and guides the targeted generation of new data where required to inform regulatory decision-making.


Elements within IATA



Six Principles: Essential Information for Regulatory Application of an IATA

1. A defined endpoint of regulatory concern
2. A defined purpose/application
3. A description of the rationale, including the mechanistic basis, underlying the construction of the IATA
4. A description of the individual information sources constituting the IATA
5. A description of how the individual information sources are integrated to derive the final prediction/assessment
6. A description of the known uncertainties

Guidance Document on the Reporting of IATA

 <p>ENV/JM/HA(2015)7 For Official Use</p>	<p>For Official Use ENV/JM/HA(2015)7</p> <p>Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 20-May-2015</p> <hr/> <p>English - Or. English</p> <p>ENVIRONMENT DIRECTORATE JOINT MEETING OF THE CHEMICALS COMMITTEE AND THE WORKING PARTY ON CHEMICALS, PESTICIDES AND BIOTECHNOLOGY</p> <p>Task Force on Hazard Assessment</p> <p>GUIDANCE DOCUMENT ON THE REPORTING OF INTEGRATED APPROACHES TO TESTING AND ASSESSMENT (IATA)</p>
---	---

Scope: To promote consistent evaluation and application of IATA within OECD member countries by providing guidance towards a harmonised approach for the reporting of IATA



IATA reporting template

1	Summary	<i>concise overview of the approach</i>
2	General information	<i>identifier, date, authors, updates, references, proprietary aspects</i>
3	Endpoint addressed	<i>e.g. skin sensitisation</i>
4	Purpose	<i>e.g. screening, hazard assessment, potency prediction</i>
5	Rationale underlying its construction	<i>including reason for the choice of information sources and their linkage to known biological mechanisms (e.g. key events)</i>
6	Brief description of the individual information sources used	<i>including response(s) measured and respective measure(s), detailed descriptions in the dedicated template</i>
7	Process applied to the derive the prediction assessment	<i>e.g. sequential testing strategies, regression models, 2 out of 3 WoE, scoring systems, machine learning approaches, Bayesian networks, etc...</i>
8	Chemicals used to develop and test the approach	<i>approach used for selection of training and test sets, relevant information on both sets: chemical names, composition, reference data (e.g. in vivo data), readouts, predictions</i>
9	Limitations (and strengths) in the application of the approach	<i>with regard to technical constrains or wrong predictions</i>
10	Predictive capacity	<i>misclassifications and unreliable predictions rationalised to the extent possible</i>
11	Known uncertainties associated with the application	<i>how key assumptions related to model structure and information sources translate to prediction uncertainty described to the extent possible</i>




European
Commission

Predictive Toxicology

Inputs

- Ambiguity
- Measurement uncertainty
- Sampling uncertainty
- Assumptions incl. default values
- Extrapolation uncertainty
- Distribution uncertainty
- Other uncertainties



Types of uncertainty

SCIENTIFIC OPINION

Guidance on Uncertainty in EFSA Scientific Assessment
EFSA Scientific Committee^{1, 2}

European Food Safety Authority (EFSA), Parma, Italy

DRAFT


ej EFSA Journal



European
Commission

ECVAM Data Base service on Alternative Methods

DB-ALM



Unclassified

ENV/JM/MONO(2014)35

Organisation de Coopération et de Développement Économiques
Organisation for Economic Co-operation and Development

15-Dec-2014

English - Or. English

ENVIRONMENT DIRECTORATE
JOINT MEETING OF THE CHEMICALS COMMITTEE AND
THE WORKING PARTY ON CHEMICALS, PESTICIDES AND BIOTECHNOLOGY

GUIDANCE DOCUMENT FOR DESCRIBING NON-GUIDELINE IN VITRO TEST METHODS

Series on Testing and Assessment
No. 211



ENV/JM/MONO(2014)35
Unclassified

<http://ecvam-dbalm.jrc.ec.europa.eu>

Joint
Research
Centre

☐ Liver slices
☐ Co-cultures
☐ Whole Organs
☐ Perfused liver

Validation of alternative methods in a regulatory context ...*the 3Ps*

*While the **principles** of validation are scientifically grounded and remain relatively constant, the **purpose** and **process** of validation need to evolve in order to keep pace with scientific progress and address the needs of decision makers.*


**Characterise reliability,
relevance, and uncertainty!**



Predictive Toxicology

Combining inputs

- Ambiguity
- Excluded factors
- Relationship between components
- Distribution uncertainty
- Structure of the assessment
- Comparisons with independent data
- Dependency between uncertainties
- Other ...



$$f(x|n) = \binom{n}{x} p^x q^{n-x}, 0 \leq x \leq n$$

$$f(x, n) = \binom{n}{x} p^x q^{n-x} a_n, 0 \leq x \leq n$$

$$m(x) = \sum_{n=x}^{\infty} \binom{n}{x} p^x q^{n-x} a_n = p^x \sum_{n=x}^{\infty} \binom{n}{x} q^{n-x} a_n =$$

$$p^x \sum_{k=0}^{\infty} \binom{x+k}{x} q^k a_{k+x}$$

$$f(n|x) = \frac{f(x, n)}{m(x)} = \frac{\binom{n}{x} p^x q^{n-x} a_n}{p^x \sum_{k=0}^{\infty} \binom{x+k}{x} q^k a_{k+x}} = \frac{\binom{n}{x} q^{n-x} a_n}{\sum_{k=0}^{\infty} \binom{x+k}{x} q^k a_{k+x}}$$

Testing Strategies (ITS / STS)

Weight of Evidence

Types of uncertainty

SCIENTIFIC OPINION

Guidance on Uncertainty in EFSA Scientific Assessment
EFSA Scientific Committee^{1, 2}

European Food Safety Authority (EFSA), Parma, Italy

DRAFT

ej EFSA Journal



European
Commission

IPCS

INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY

IPCS Harmonization Project



World Health
Organization

Guidance Document on Evaluating and Expressing Uncertainty in Hazard Characterization

Problem formulation

For example:

- Risk management scope and goals of assessment
- Choice of relevant exposure scenarios
- Analysis plan and information needs
- Choice of hazard assessment end-points
- Acceptable levels of uncertainty and risk

Dose-response
assessment

Mode of action
considerations

Hazard
assessment

Uncertainty analysis
options:

- Qualitative
- Non-probabilistic
- Approximate probabilistic
- Full probabilistic

Uncertainty analysis informs

- Risk management and socioeconomic impacts
- Risk assessment and derivation of reference doses
- Characterization of and comparison across hazard data sets
- Application of mode of action analysis and further refinement of hazard characterization using other methodologies

Fig. 2.1: Uncertainty analysis in the context of problem formulation.



European
Commission

*Molecular
Events*

*Organelle
Events*

*Cellular
Events*

HTS “Toxicity” pathway assay

6. Implement and optimise for running on a HTS platform

4. Characterise and describe pathway response dynamics

2. Selection and characterisation of cellular model expressing the physiological pathway

Physiological pathway


7. Validation of assay performance using a limited chemical set

5. Select optimum in vitro assay operational parameters

3. Select sensitive/specific biomarkers and probe-chemicals to measure pathway response

1. Selection of physiological pathway that has toxicological relevance

Expert system decision tree for repro/dev toxicity





OECD AOP Development Programme

Responsibility of the Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST)

Co-chairs: Robert Kavlock (US EPA) & Maurice Whelan (EC JRC)

Development of AOP



Villeneuve et. al., (2014) 'Adverse Outcome Pathway (AOP) Development I: Strategies and Principles', *Toxicol. Sci.*, 142 (2), 312-320.

Villeneuve et. al. (2014), 'Adverse Outcome Pathway (AOP) Development II: Best Practices', *Toxicol. Sci.*, 142 (2), 321-330.

Evidence in the literature?

- *OECD Template and Guidance on developing and assessing the completeness of Adverse Outcome Pathways (2013)*
- *Supplementary 'User Handbook' (Sept 2014).*



Adverse Outcome Pathway Knowledge Base (AOP-KB)

|| AOP-KB || Background || How to contribute ||

www.aopkb.org

AOP Wiki

Adverse Outcome Pathway Knowledge Base (AOP-KB)

|| AOP-KB || Background || How to contribute ||

How to contribute

Adverse outcome pathways can be viewed as an organized representation of existing knowledge concerning the linkage between a chemical perturbation of a biomolecule (i.e., the molecular initiating event (MIE)), progressing through intermediate key events (KE) and culminating with an adverse outcome (AO) relevant for risk assessment.


If you are interested in contributing AOP-related knowledge to the AOP-KB, please follow the instructions laid out at the [OECD Adverse Outcome Pathways, Molecular Screening and Toxicogenomics page](#).

The [Guidance on Developing and Assessing AOPs document](#) is the basis for all work related to contributing and sharing AOP-related knowledge. A [Users' Handbook Supplement](#) to this Guidance has been written to aid systematic development and transparent assessment of Adverse Outcome Pathways (AOPs). The handbook contains a template to guide AOP description and provides focused and practical instructions for developers and assessors intended to assist in identifying, organizing, and evaluating critical information on key events and linkages (i.e., key event relationships (KER)) within the AOP, as well as guidance on how to assess the weight of evidence supporting the overall AOP.

Please click on any of the AOPs
Please note that the AOP-KB is



AOP Wiki – Document (Article) structure






AOP Knowledge Base

AOPs Under Development



- AhR activation leading to embryo toxicity in fish
- Androgen receptor antagonism leading to adverse effects in the male foetus (mammals)
- Androgen receptor antagonism leading to reproductive dysfunction
- Binding to glutamatergic ionotropic receptors can trigger neuroinflammation leading to neurodegeneration
- Binding of antagonist to N-methyl-D-aspartate (NMDA) receptors during brain development (synaptogenesis) induces impairment of learning and memory abilities
- Binding of agonists to N-methyl-D-aspartate receptor (NMDAR) in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to reduction (or loss) of cognitive function
- Binding of antagonists to NMDAR can trigger neuroinflammation leading to neurodegeneration
- Binding to electron chain transfer complexes in the mitochondria can trigger neuroinflammation and lead to neurodegeneration
- Binding to SH/selen-proteins can trigger neuroinflammation leading to neurodegeneration
- Calcium-mediated neuronal ROS production and energy imbalance
- Cyclooxygenase inhibition leading reproductive failure
- Ecdysone receptor (EcR) activation leading to mortality in *Daphnia magna*
- Estrogen receptor agonism leading to reproductive dysfunction
- Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility
- Inhibition of complex I of the mitochondrial respiration chain leading to neurodegeneration.
- Inhibition of IRVUS, hepatic, and regenerative capacity leading to liver tumors
- Kidney toxicity induced by inhibition of EMT
- LXR Activation to Liver Steatosis
- Multiple Molecular Initiators trigger Neuronal Inflammation leading to Neurodegeneration
- AFB1 damage to liver leading to Hepatocellular Carcinoma (HCC)
- Na⁺ channel dysfunction leading to respiratory failure
- Peroxisomal Fatty Acid Beta-Oxidation Inhibition leading to liver steatosis
- PPAR alpha activation leading to decreased fertility upon utero exposure in male rodents
- PPARalpha-dependent liver cancer
- PPARγ activation leading to decreased fertility in adult female rodents
- Respiratory Sensitization/Allergy induced by covalent binding to proteins
- Skin Sensitisation Initiated by Covalent Binding to Proteins
- Sustained AhR Activation leading to Rodent Liver Tumours
- Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals
- VEGF Signaling and Vascular Disruption Leading to Adverse Developmental Outcomes
- PPARα activation leading to impaired fertility in adult male rodents
- Inhibition of Na⁺/I⁻ symporter (NIS) decreases TH synthesis leading to learning and memory deficits in children



To conclude ...

- IATA ... an international standard for reporting hazard and risk assessments (approaches) based on the integration of predictive toxicology methods.
- We shouldn't 'reinvent the wheel' when it comes to assessing and describing uncertainty within/of IATA but instead adapt existing (excellent) guidance.
- The need/use of mode-of-action knowledge is the major difference between hazard/risk assessment based on conventional and predictive toxicology.
- The 'unfamiliar' uncertainties will become familiar when we start identifying and characterising them!
Validation can help!

Transitioning to a new way of describing toxicological hazard ...?





European
Commission

Joint Research Centre (JRC)

The European Commission's in-house science service



www.jrc.ec.europa.eu

Serving society - Stimulating innovation - Supporting legislation

DISCLAIMER: This presentation and its contents do not constitute an official position of the European Commission or any of its services. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of this presentation or its contents

Joint
Research
Centre